On September 9, Oscar Health, Inc. fell 5.15% in regular trading, trading at $31.34/share, with turnover of $13.61 million. The decline came amid intensified concerns over a wave of insider selling and a previously flagged risk of accelerating membership losses.

On the news front, the company disclosed five insider transactions on September 8. Co-founder and director Mario Schlosser sold 600,000 shares on August 28 and an additional 31,400 shares on September 3, while executive Richard Scott Blackley sold 18,800 shares on August 18. The concentrated insider disposals have heightened market unease about management confidence. Notably, Schlosser transitioned from his Chief Technology Officer role to an advisory position in June, and the subsequent large-scale share sales have further amplified bearish sentiment.

While Q2 results were strong — revenue of $4.88 billion and EPS of $1.10 both significantly exceeded consensus estimates of $4.75 billion and $0.42 respectively — the company simultaneously warned that ACA membership churn would accelerate in the second half. Total members stood at approximately 2.96 million as of June 30, up 46% year-over-year, but the sustainability of that growth trajectory is now in question. UBS maintained a Neutral rating in August with a $26 price target, reflecting a cautious Street outlook.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)